Rogerio Vivaldi, M.D., M.B.A. is the President and Chief Executive Officer of Sigilon Therapeutics. During his more than 25 years as a physician and an industry executive, Dr. Vivaldi has built a reputation as a devoted advocate for patients, particularly those with chronic diseases.

Most recently, he served as Executive Vice President and Chief Global Therapeutic Operations Officer at Bioverativ, which was acquired in 2018 by Sanofi for $11.6 billion. Prior to Bioverativ, Dr. Vivaldi was Chief Commercial Officer at Spark Therapeutics, where he worked to commercialize the company’s gene therapeutics. He also managed Spark’s Medical Affairs and Patient Advocacy groups.

Prior to Spark, Dr. Vivaldi co-founded and served as President and CEO of Minerva Neurosciences, a clinical-stage company developing products for patients with neuropsychiatric diseases. Before co-founding Minerva, he led Genzyme’s rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme’s Latin America Group during his almost 20-year tenure at Genzyme.

Dr. Vivaldi was the first physician in Latin America to manage Enzyme Replacement Therapy (ERT) for a patient with Gaucher Disease back in 1991. He ran an endocrinology clinic primarily focused on type 1 diabetes for 18 years and is himself a person with type 1 diabetes.

Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro (UNIRIO). He completed a residency in endocrinology at Universidade do Estado do Rio de Janeiro (UERJ) and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. He also holds an MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro (UFRJ).